Sacituzumab
Based on 9 publication(s) in Google Scholar
Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer.
For research use only. We do not sell to patients.
- Purity : 99.9%
- CAS No.: 1796566-95-4
- Molecular Weight:145.52 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Sacituzumab
More- Nat Commun. 2026 Apr 23;17(1):5600. [Abstract]
- J Nanobiotechnology. 2025 Dec 16;24(1):58. [Abstract]
- J Immunother Cancer. 2026 May 7;14(5):e014671. [Abstract]
- Bioconjug Chem. 2025 Aug 21. [Abstract]
- J Chromatogr A. 2026 Jun 21:1777:466966. [Abstract]
- bioRxiv. 2026 May 27.
- Patent. US20260027227A1.
- Patent. US20250320310A1.
- KTH Royal Institute of Technology. 2025.
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
TROP2
In Vitro
Sacituzumab (0.5 nM, 800 s) possesses non-competitive binding sites and recognized distinct epitopes of TROP-2 on the antigen. Additionally, the binding to cancer cell lines activities of Sacituzumab and hIMB1636 is similar[1]. Sacituzumab (5 mg/mL, 48 h) binds to a linear epitope within TROP-2, which might not interrupt the assembly of TROP-2 molecules on the cell surface in HEK-293T cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HEK-293T cells
-
Concentration:5 mg/mL
-
Incubation Time:48 h
-
Result:Bounded to the linear epitopes of denatured TROP-2 proteins in HEK 293T cells.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MDA-MB-468 xenograft model of 6-week-old female BALB/c nude mice[1]
-
Dosage:50 mg/kg
-
Administration:i.v., intervals of 5 days and repeated a total of four times
-
Result:Decreased the tumor inhibition rate to 29.1% at 50 mg/kg in MDA-MB-468 xenograft model.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Loaded Sacituzumab on AHC2 biosensor, can bind TROP-2 Protein, Human (248a.a, HEK293, His, HY-P70457) with an affinity constant of 8.077E-10 M as determined in BLI assay. -
-
Chemical Information
-
CAS No. 1796566-95-4
-
Appearance Liquid
-
Molecular Weight 145.52 kDa
-
Color Colorless to light yellow
-
SMILES
[Sacituzumab]
-
Synonyms
HRS7; hRS7
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
High-throughput single-vesicle imaging platform for direct extracellular vesicle profiling of human plasma. [Abstract]2026 Apr 23;17(1):5600. PMID: 42020418 -
J Nanobiotechnology
Inverse-designed plasmonic biosensors with LSPR-SPP-wood anomaly coupling enhanced for biomolecular analysis. [Abstract]2025 Dec 16;24(1):58. PMID: 41402825 -
J Immunother Cancer
Endogenous neoantigen-specific antibodies mediate antitumor responses and determine vaccine efficacy. [Abstract]2026 May 7;14(5):e014671. PMID: 42097835 -
Bioconjug Chem
Resin-Supported Site-Specific Antibody Conjugation Method Leads to Antibody-Drug Conjugates with Retained Efficacy and Improved Stability. [Abstract]2025 Aug 21. PMID: 40839643 -
J Chromatogr A
Comprehensive evaluation of the analytical toolbox for commercial cysteine-linked antibody-drug conjugates. [Abstract]2026 Jun 21:1777:466966. PMID: 41962243 -
-
-
-
Protocols
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Zhou DD, et al. Elucidating the development, characterization, and antitumor potential of a novel humanized antibody against Trop2[J]. Int J Biol Macromol. 2023 Dec 31;253(Pt 6):127105. [Content Brief]
[2]. Sun M, et al. Structural insights into the cis and trans assembly of human trophoblast cell surface antigen 2[J]. iScience. 2021 Sep 30;24(10):103190. [Content Brief]
[3]. Shih LB, et al. In vitro and in vivo reactivity of an internalizing antibody, RS7, with human breast cancer[J]. Cancer Res. 1995 Dec 1;55(23 Suppl):5857s-5863s. [Content Brief]
[4]. Bardia A, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol. 2021 Sep;32(9):1148-1156. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)